theranostics May 16, 2022 Point Biopharma to Launch Phase I Study of FAP-Targeted Radiopharmaceutical in Canada May 11, 2022 NCCN, SNMMI Update Guidelines to Expand PET Imaging Agents for Pluvicto Eligibility May 5, 2022 Novartis Pauses US Pluvicto Production Due to Possible Quality Issues May 5, 2022 Telix Pharmaceuticals Doses First Kidney Cancer Patient in Radiopharmaceutical Trial Apr 11, 2022 Telix Acquires Exclusive Worldwide Rights to Eli Lilly's Olaratumab Mar 29, 2022 Novartis, Lantheus Partner on PSMA Imaging-Based Patient Selection in Pluvicto Trials Mar 14, 2022 Bracco Imaging Spins Out Blue Earth Therapeutics as 'Sister Company' to Dx Subsidiary Premium Feb 3, 2022 Novartis Anticipating Radioligands, New Precision Therapies to Continue Oncology Segment Growth Premium Jan 3, 2022 With New Cancer Theranostics Poised to Enter the Market, Access Disparities Loom Premium Nov 10, 2021 Isotopia, Peter MacCallum Cancer Centre Partner on Prostate Cancer Radiopharmaceutical Study May 4, 2021 FDA Accepts IND for Clarity Pharmaceuticals' Prostate Cancer Radiopharmaceutical Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
